Erik Ibarra's latest venture is to give agency to residents in the neighborhood he grew up in. Photo courtesy

Innovation isn't always tinkering with tech or programming software, although serial entrepreneur Erik Ibarra knows that world well. Sometimes it's about rethinking how a community improves and develops without doing the residents a disservice.

That's why Ibarra started Magnolia Fund, a mission-driven investment fund dedicated to enriching the East End community and preserving the neighborhood's culture and history. Ibarra, who has lived in the area the majority of his life, says on the Houston Innovators Podcast, that he's looking to turn residents into investors.

"Our investors from the neighborhood, today they walk around and look at their house and say, 'I own that,' and that's great," Ibarra says. "In the future, our investors should be able to say that, and then point to a building and say, 'I own a portion of that building too. And I helped that small business over there.'"

Ibarra explains that he's seen the East End area evolve a lot, and he wants to create a way to make sure residents are a part of that evolution and aren't being left behind in that process.

"Over the years, I've felt like there's so much development going on. But, the people from the neighborhood are very often just passive — they don't get a chance to benefit from or think about how they could participate in these new developments," Ibarra says. "The neighborhood is very close to my heart, and, about a year ago, I realized I wanted to do something about this."

The limited partners of the Magnolia Fund will contribute as investors, and then Ibarra and his team will identify a worthy development to take control of. As he explains, the vision for the property is "La Sala," a living room for the community, with an open area for communing, a kitchen incubator for food entrepreneurs, and an outdoor patio and stage for music and events.

While this is his first foray into the investor side of the equation, Ibarra has been an entrepreneur in Houston since the early 2000s. He's been an active mentor to startup founders, and has seen the ecosystem develop as he's started and grown his businesses.

He's currently the founder and CEO of ORDRS, a digital health platform for optimized lab testing founded in 2018. The company's B2B platform enables health care providers to better manage lab testing, and Ibarra says ORDRS saw a lot of growth during the pandemic. Something he's passionate about with this venture is the ability to provide better access and information about lab testing to patients.

"As a company we strive for transparency in health care," Ibarra says. "If we could provide instant access to a menu of tests for our customers, ... then hopefully our customers can pass those savings on to those customers. Access to testing is important. Access to the transparency in pricing is equally important."

Ibarra shares more about ORDRS, his role as a mentor, and his vision for the fund on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Words of wisdom from a founder who's done this all before. And then again. And again. Photo via Getty Images

4 lessons learned from this Houston-based serial entrepreneur

guest column

A true test to determine if you are an entrepreneur is knowing if you can recognize your failures. From the outside, we often think of every business leader as having a resume of success stories. You see CEOs in magazines, on television, and in the news, but what you don’t always see is their often-endless list of ideas and decisions that simply didn’t work. Those failures may include a startup that didn’t launch or a key decision that went sideways. Either way, these missteps are often there if you listen to their stories or look hard enough.

I’m not immune to making mistakes. As a serial entrepreneur and having started, led, and mentored various successful companies, I have made some mistakes and have been lucky enough to learn from them. Below is a list of key takeaways I’ve compiled from years of learning.

1. Know what kind of entrepreneur you are.

Before you even get to the service or product that you want to create, learn a little bit about who you are as a leader. Check out a BOSI assessment online to help you determine if you are a Builder, Opportunist, Specialist, or Innovator. Knowing and utilizing your strengths as well as looking for help with your weaknesses will take you far. This also will make a big difference if you are searching for a co-founder. When I started Pinot’s Palette, my co-founder and I both were strong Builders. Without understanding this ahead of time, we ended up wasting time and money overbuilding features that didn’t need to be perfected pre-launch. Looking back, we could have benefited from adding an Opportunist to our team early on and focusing our time on our strengths.

2. You pay for experience….one way or another.

I can’t take full credit for this lesson. My mentor, Dr. Al Napier, shared this sentiment with me years ago. The concept is that you will either pay an in-house expert or consultant early on or you will pay for the mistakes you make with scar tissue. Sometimes, those mistakes can be detrimental. Of course, there’s a time and place to spend money and you don’t want to overspend early, but you need to balance bootstrapping with deploying capital to prevent a game-ending error.

3. Truly understand your vision and how to implement it. 

Staying focused isn’t always easy. You have an idea, but how do you get from step 1 to success? It’s easy to get off track and go down the wrong path – a critical error! As Lori Clements taught me, utilizing EOS (Entrepreneurial Operating System) to organize your vision and stay disciplined will ultimately help you become a better leader. I started working with an EOS coach back in my Pinot’s Palette days and it was a game-changer for how we solved problems. Now, I recommend it to every budding entrepreneur.

4. Build your support network early.

Having a support system in every aspect of life is important. In business, having the right people to lean on and run ideas by can be vital. For each business that I’ve started, there have been emotional and mental hardships to work through. You have your business “baby” and often employees leaning on you to make the right decisions. You can find a professional network through your alumni groups or just seek out other entrepreneurs also going through a similar phase in their business.

Ultimately, you need to be mentally prepared, knowing there will be ups and downs in your business. There is no way to prevent all errors but hopefully turning the mistakes into lessons is what defines leaders.

------

Craig Ceccanti is a serial entrepreneur and has co-founded Houston-based Rivalry Technologies and Pinot's Palette. He is the founder, president, and CEO of T-Minus Solutions, a software company.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.